A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population

•Co-occurring genomic alterations at diagnosis might represent de novo and primary resistance mechanisms to tyrosine kinase inhibitors (TKIs) in advanced EGFR-mutant (EGFRm) non-small lung cancer (NSCLC).•In this study, we assessed the prognostic role of co-occurring genomic alterations in advanced EGFRm NSCLC.•TP53 mutations are the most frequent alteration associated in LATAM patients with EGFRm NSCLC and are associated with a worse overall prognosis.•Our study demonstrates that EGFRm NSCLC is not a single oncogene-driven disease, and an increased number of co-occurring genetic alterations negatively impact the PFS in the LATAM population.